With generic medicines, Italian public health saves one billion euros a year. And of these, a good 200 million are the contribution made by Teva Italia, a company that alone holds the 20% of the generics market. This is what emerges from a research conducted by The European House – Ambrosetti, presented in Rome during a meeting at the Ministry of Health entitled “Twenty years of Teva in Italy. Growth, innovation and value for the country”.
“The contribution that large pharmaceutical companies can make in terms of citizens' rights can be very important”, explains Antonio Gaudioso, general secretary of Cittadinanzattiva. "Not only - he adds - because they produce economic value, jobs and related industries, but also because they invest in research, which means new possibilities for treatment for patients". In the case of Teva, more than 60 people are employed in drug research and development, while on the clinical research front, the company has ongoing studies involving more than 1,000 patients in more than 150 centres. “Corporate strategies and innovation have always had, and still have today, – he commented Hubert Puech d'Alissac, CEO of Teva Italia – people at the centre. Our goal is to respond to the growing therapeutic needs and to contribute to the improvement of patients' quality of life, in particular by investing in innovative drugs, both oncological and for the central nervous system"
October 7, 2016 – Daily Health Industry
Related news: Vito de Filippo at the twentieth Teva anniversary. Sustainability NHS, from adherence to therapy to cuts in healthcare
Teva sells Actavis Generics business in UK and Ireland to Intas of India
